About IDEXX Laboratories Inc
Ticker
info
IDXX
Trading on
info
NASDAQ
ISIN
info
US45168D1046
Industry
info
Diagnostics & Research
Sector
info
Healthcare
CEO
info
Jonathan J. Mazelsky
Headquarters
info
One IDEXX Drive, Westbrook, ME, United States, 04092
Employees
info
11,000
Website
info
idexx.com
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It offers in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology, and coagulation analyzers; and SNAP rapid assays test kits. The company also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, it offers diagnostic tests, services, and related instrumentation for manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Metrics
BasicAdvanced
Market cap
info
$34.6B
P/E ratio
info
39.54
EPS
info
$10.79
Dividend Yield
info
0.00%
Beta
info
1.5
Forward P/E ratio
info
35.97
EBIDTA
info
$1.32B
Ex dividend date
info
-
Price & volume
Market cap
info
$34.6B
Average daily volume
info
1.1M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
39.54
Forward P/E
info
35.97
PEG ratio
info
3.63
Trailing P/E
info
39.54
Price to sales
info
8.87
Price to book
info
21.67
Earnings
EPS
info
$10.79
EPS estimate (current quarter)
info
$2.40
EPS estimate (next quarter)
info
$3.00
EBITDA
info
$1.32B
Revenues (TTM)
info
$3.9B
Revenues per share (TTM)
info
$47.26
Technicals
Beta
info
1.5
52-week High
info
$548.88
52-week Low
info
$356.14
50-day moving average
info
$425.21
200-day moving average
info
$448.98
Short ratio
info
3.77
Short %
info
4.56%
Management effectiveness
ROE (TTM)
info
57.66%
ROA (TTM)
info
22.69%
Profit margin
info
22.78%
Gross profit margin
info
$2.38B
Operating margin
info
27.42%
Growth
Quarterly earnings growth (YoY)
info
13.40%
Quarterly revenue growth (YoY)
info
5.80%
Share stats
Outstanding Shares
info
81M
Float
info
80.4M
Insiders %
info
0.66%
Institutions %
info
93.56%
Analyst Insights & forecasts
info

47% Buy

53% Hold

0% Sell

Based on information from 13 analysts.

Average price target

info
$486.13
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
$2.81
$2.67
5.24%
Q1 • 24Beat
$3.02
$2.88
4.86%
Q2 • 24Beat
$2.80
$2.68
4.48%
Q3 • 24Beat
$2.62
$2.40
9.17%
Q4 • 24Beat
-
-
-
Q1 • 25Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$976M
$233M
23.87%
Q3 • 24
$954M
$216M
22.65%
Q4 • 24
2.18%
7.17%
5.10%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$3.35B
$1.73B
51.71%
Q3 • 24
$3.29B
$1.7B
51.56%
Q4 • 24
1.71%
2.00%
0.29%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$220M
$-27.4M
$-291M
$192M
Q3 • 24
$262M
$-39.8M
$-233M
$223M
Q4 • 24
19.06%
45.58%
20.00%
16.03%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a IDEXX Laboratories Inc share?
Collapse

IDEXX Laboratories Inc shares are currently traded for undefined per share.

How many shares does IDEXX Laboratories Inc have?
Collapse

IDEXX Laboratories Inc currently has 81M shares.

Does IDEXX Laboratories Inc pay dividends?
Collapse

No, IDEXX Laboratories Inc doesn't pay dividends.

What is IDEXX Laboratories Inc 52 week high?
Collapse

IDEXX Laboratories Inc 52 week high is $548.88.

What is IDEXX Laboratories Inc 52 week low?
Collapse

IDEXX Laboratories Inc 52 week low is $356.14.

What is the 200-day moving average of IDEXX Laboratories Inc?
Collapse

IDEXX Laboratories Inc 200-day moving average is $448.98.

Who is IDEXX Laboratories Inc CEO?
Collapse

The CEO of IDEXX Laboratories Inc is Jonathan J. Mazelsky.

How many employees IDEXX Laboratories Inc has?
Collapse

IDEXX Laboratories Inc has 11,000 employees.

What is the market cap of IDEXX Laboratories Inc?
Collapse

The market cap of IDEXX Laboratories Inc is $34.6B.

What is the P/E of IDEXX Laboratories Inc?
Collapse

The current P/E of IDEXX Laboratories Inc is 39.54.

What is the EPS of IDEXX Laboratories Inc?
Collapse

The EPS of IDEXX Laboratories Inc is $10.79.

What is the PEG Ratio of IDEXX Laboratories Inc?
Collapse

The PEG Ratio of IDEXX Laboratories Inc is 3.63.

What do analysts say about IDEXX Laboratories Inc?
Collapse

According to the analysts IDEXX Laboratories Inc is considered a hold.